Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
DBV Technologies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
DBV Technologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
DBV Technologies's earnings are expected to grow significantly at over 20% yearly.
DBV Technologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
DBV Technologies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
DBV Technologies's finances.
The net worth of a company is the difference between its assets and liabilities.
DBV Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
DBV Technologies's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
DBV Technologies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 58.7x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Daniel Tassé has been the Chief Executive Officer at DBV Technologies S.A. since November 29, 2018 and has been its Director since March 5, 2019. He served as the Chairman and Chief Executive Officer of Alcresta Therapeutics, Inc. Mr. Tassé serves as Senior Advisor at Bridge Growth Partners, LLC. An accomplished healthcare executive, he has built and led businesses with global footprints in the fields of bio-pharmaceuticals, medical devices, diagnostics and health services. Prior to the acquisition of Ikaria by Mallinckrodt in April 2015, Mr. Tassé was President and Chief Executive Officer and Chairman of the Board of Ikaria and served as Interim Chief Executive Officer and President of Bellerophon Therapeutics, Inc. from February 2014 to June 2014. He has more than 35 years of biopharmaceutical leadership experience. He served as the Chairman of the Board of Ikaria, Inc. since October 2009 until 2015 and its Chief Executive Officer and President since January 2008 until April 2015. Mr. Tassé served as the General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc. He served as President and Regional Director for Australasia at GlaxoSmithKline from 2001 to 2004. He held management positions at Upjohn. He has been Director at Bellerophon Therapeutics, Inc. since February 2014. Mr. Tassé has been an Independent Director of Regenxbio Inc. since August 2016. Mr. Tassé has been an Independent Non-Executive Director of Indivior PLC since November 04, 2014 and has been its Senior Independent Director since September 30, 2016. He was an Independent Director of HLS Therapeutics Inc. He serves as a Member of Technology Advisory Board and Member of Strategic Advisory Board at Bridge Growth Partners, LLC. He has been Director of BioQ Pharma Incorporated since July 2015. He served as a Director and a Member of Health Section Governing Board at Biotechnology Innovation Organization from July 2011 to June 2015. He served as a Director of Ikaria Holdings, Inc. since January 2008 until April 2015. From 2011 to 2015, he served as a Board Director of PhRMA. He serves as the Chairman of the Foundation on National Critical Care Policy. He serves at the Sheikh Zayed Institute Business Advisory Council in DC. He is a board director of the Roundtable on Critical Care Policy. He was a Member of the Healthcare Leadership Council from 2010 to June 2015. Mr. Tassé holds a B.Sc. in Biochemistry from the University of Montreal and is fluent in both French and English.
Insufficient data for Daniel to compare compensation growth.
Insufficient data for Daniel to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the DBV Technologies management team is about average.
Co-Founder & Member of Scientific Advisory Board
Deputy CEO & CFO
Deputy CEO & Responsible Pharmacist
CEO & Director
Interim Chief Medical Officer
Director of Investor Relations & Strategy
Chief Legal Officer
Vice President of Global Corporate Communications
Chief Clinical Trial Officer & Senior VP
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the DBV Technologies board of directors is less than 3 years, this suggests a new board.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn’s disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.